---
title: "Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect"
description: "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased TransMedics Group, Inc. (TMDX) securities before February 3, 2022. The investigation focuses o"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252384534.md"
published_at: "2025-08-10T15:00:02.000Z"
---

# Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect

> Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased TransMedics Group, Inc. (TMDX) securities before February 3, 2022. The investigation focuses on possible corporate wrongdoing by TransMedics and its officers. Investors are encouraged to visit bgandg.com/TMDX for more information and to assist in the investigation. The firm operates on a contingency fee basis, meaning they only charge if successful in recovering funds for investors.

NEW YORK CITY, NY / ACCESS Newswire / August 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") . Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.

**Investigation Details**

The investigation concerns whether TransMedics and certain of its officers and/or directors have engaged in corporate wrongdoing.

**What's Next?**

If you are aware of any facts relating to this investigation or purchased TransMedics shares, you can assist this investigation by visiting the firm's site: bgandg.com/TMDX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC:

**There is No Cost to You**

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

**Why Bronstein, Gewirtz & Grossman**

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

**Contact**

**SOURCE:** Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire

### Related Stocks

- [TMDX.US - TransMedics](https://longbridge.com/en/quote/TMDX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| TransMedics erhält vollständige FDA-IDE-Zulassung für OCS Heart ENHANCE Trial | TransMedics Group Inc. has received full and unrestricted approval from the U.S. Food and Drug Administration (FDA) for  | [Link](https://longbridge.com/en/news/275321278.md) |
| TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts \| TMDX Stock News | TransMedics Group, Inc. has announced the signing of a long-term lease for its new global headquarters at Assembly Innov | [Link](https://longbridge.com/en/news/272275112.md) |
| Here's How Much $1000 Invested In TransMedics Group 5 Years Ago Would Be Worth Today | Investing $1000 in TransMedics Group (NASDAQ:TMDX) 5 years ago would now be worth $6,750.92, reflecting an annualized re | [Link](https://longbridge.com/en/news/270664120.md) |
| TransMedics Group Inc. Unveils Presentation on Revolutionizing Organ Transplantation with OCS Platform | TransMedics Group Inc. has unveiled a presentation on its innovative Organ Care System (OCS) platform, which addresses t | [Link](https://longbridge.com/en/news/272332645.md) |
| How Is The Market Feeling About TransMedics Group Inc? | TransMedics Group Inc (NYSE:TMDX) has seen a 9.35% decrease in short interest, with 7.00 million shares sold short, repr | [Link](https://longbridge.com/en/news/271347380.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.